Top

Published in:

Open Access 01-12-2016 | Research article

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Authors: James M. Cleary, Harvey J. Mamon, Jackie Szymonifka, Raphael Bueno, Noah Choi, Dean M. Donahue, Panos M. Fidias, Henning A. Gaissert, Michael T. Jaklitsch, Matthew H. Kulke, Thomas P. Lynch, Steven J. Mentzer, Jeffrey A. Meyerhardt, Richard S. Swanson, John Wain, Charles S. Fuchs, Peter C. Enzinger

Published in: BMC Cancer | Issue 1/2016

Abstract

Background

Patients with locally advanced esophageal cancer who are treated with trimodality therapy have a high recurrence rate. Preclinical evidence suggests that inhibition of cyclooxygenase 2 (COX2) increases the effectiveness of chemoradiation, and observational studies in humans suggest that COX-2 inhibition may reduce esophageal cancer risk. This trial tested the safety and efficacy of combining a COX2 inhibitor, celecoxib, with neoadjuvant irinotecan/cisplatin chemoradiation.

Methods

This single arm phase 2 trial combined irinotecan, cisplatin, and celecoxib with concurrent radiation therapy. Patients with stage IIA-IVA esophageal cancer received weekly cisplatin 30 mg/m² plus irinotecan 65 mg/m² on weeks 1, 2, 4, and 5 concurrently with 5040 cGy of radiation therapy. Celecoxib 400 mg was taken orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery.

Results

Forty patients were enrolled with stage IIa (30 %), stage IIb (20 %), stage III (22.5 %), and stage IVA (27.5 %) esophageal or gastroesophageal junction cancer (AJCC, 5th Edition). During chemoradiation, grade 3–4 treatment-related toxicity included dysphagia (20 %), anorexia (17.5 %), dehydration (17.5 %), nausea (15 %), neutropenia (12.5 %), diarrhea (10 %), fatigue (7.5 %), and febrile neutropenia (7.5 %). The pathological complete response rate was 32.5 %. The median progression free survival was 15.7 months and the median overall survival was 34.7 months. 15 % (n = 6) of patients treated on this study developed brain metastases.

Conclusions

The addition of celecoxib to neoadjuvant cisplatin-irinotecan chemoradiation was tolerable; however, overall survival appeared comparable to prior studies using neoadjuvant cisplatin-irinotecan chemoradiation alone. Further studies adding celecoxib to neoadjuvant chemoradiation in esophageal cancer are not warranted.

Trial registration

Clinicaltrials.gov: NCT00137852, registered August 29, 2005.

Enzinger PC, Mayer RJ. Esophageal Cancer. N Engl J Med. 2003;349(23):2241–52. doi:10.1056/NEJMra035010.CrossRefPubMed

Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. doi:10.1016/s1470-2045(11)70142-5.CrossRefPubMed

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–34. doi:10.1016/S1470-2045(07)70039-6.CrossRefPubMed

Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, et al. American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal Adenocarcinoma. J Clin Oncol. 2007;25(5):507–12. doi:10.1200/jco.2006.08.0101.CrossRefPubMed

Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival. J Clin Oncol. 2005;23(19):4330–7. doi:10.1200/jco.2005.05.017.CrossRefPubMed

Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55. doi:10.1002/cncr.20916.CrossRefPubMed

Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, et al. Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival. Ann Thorac Surg. 2009;87(2):392–9. doi:10.1016/j.athoracsur.2008.11.001.CrossRefPubMedPubMedCentral

Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92. doi:10.1200/jco.2007.12.9593.CrossRefPubMed

Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma. N Engl J Med. 1996;335(7):462–7. doi:10.1056/NEJM199608153350702.CrossRefPubMed

10.

van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIB, Wijnhoven BPL, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med. 2012;366(22):2074–84. doi:10.1056/NEJMoa1112088.CrossRefPubMed

11.

Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, et al. Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer. J Clin Oncol. 1999;17(10):3270–5.PubMed

12.

Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncol (Williston Park, NY). 2001;15(3 Suppl 5):52–4.

13.

Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer. 2010;116(17):4023–32. doi:10.1002/cncr.25349.CrossRefPubMed

14.

Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2012;118(11):2820–7. doi:10.1002/cncr.26591.CrossRefPubMed

15.

Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. N Engl J Med. 2003;348(10):891–9. doi:10.1056/NEJMoa021735.CrossRefPubMed

16.

Chan AT, Ogino S, Fuchs CS. Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. N Engl J Med. 2007;356(21):2131–42. doi:10.1056/NEJMoa067208.CrossRefPubMed

17.

Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. N Engl J Med. 2012;367(17):1596–606. doi:10.1056/NEJMoa1207756.CrossRefPubMedPubMedCentral

18.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the Prevention of Sporadic Colorectal Adenomas. N Engl J Med. 2006;355(9):873–84. doi:10.1056/NEJMoa061355.CrossRefPubMed

19.

Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib for the Prevention of Colorectal Adenomatous Polyps. N Engl J Med. 2006;355(9):885–95. doi:10.1056/NEJMoa061652.CrossRefPubMed

20.

Prins MJD, Verhage RJJ, Kate FJW, Hillegersberg R. Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma. J Gastrointest Surg. 2012;16(5):956–66. doi:10.1007/s11605-011-1814-1.CrossRefPubMedPubMedCentral

21.

Hashimoto N, Inayama M, Fujishima M, Shiozaki H. Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma. Hepato-Gastroenterology. 2007;54(75):758–60.PubMed

22.

Takatori H, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008;34(4):397–402. doi:10.1016/j.ejso.2007.04.011.CrossRefPubMed

23.

Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, et al. Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis. Clin Cancer Res. 2004;10(19):6703–9. doi:10.1158/1078-0432.ccr-04-0838.CrossRefPubMed

24.

Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, et al. NADPH Oxidase NOX5-S Mediates Acid-induced Cyclooxygenase-2 Expression via Activation of NF-kBin Barrett's Esophageal Adenocarcinoma Cells. J Biol Chem. 2007;282(22):16244–55. doi:10.1074/jbc.M700297200.CrossRefPubMed

25.

Furuta Y, Hunter N, Barkley T, Hall E, Milas L. Increase in Radioresponse of Murine Tumors by Treatment with Indomethacin. Cancer Res. 1988;48(11):3008–13.PubMed

26.

Palayoor ST, Arayankalayil MJ, Shoaibi A, Coleman CN. Radiation Sensitivity of Human Carcinoma Cells Transfected with Small Interfering RNA Targeted against Cyclooxygenase-2. Clin Cancer Res. 2005;11(19):6980–6. doi:10.1158/1078-0432.ccr-05-0326.CrossRefPubMed

27.

Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, et al. COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2011;18(10):2946–51. doi:10.1245/s10434-011-1645-z.CrossRefPubMed

28.

Nix P, Lind M, Greenman J, Stafford N, Cawkwell L. Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol. 2004;15(5):797–801. doi:10.1093/annonc/mdh185.CrossRefPubMed

29.

Smith FM, Reynolds JV, Kay EW, Crotty P, Murphy JO, Hollywood D, et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys. 2006;64(2):466–72. doi:10.1016/j.ijrobp.2005.07.961.CrossRefPubMed

30.

Cancer AJCo. Cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.

31.

Altorki NK, Christos P, Port JL, Lee PC, Mirza F, Spinelli C et al. Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial. Journal of Thoracic Oncology.6(6):1121–7. doi:10.1097/JTO.0b013e31821529a9

32.

Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncol (Williston Park, NY). 2004;18(14):18–21.

33.

Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, et al. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Investig New Drugs. 2006;25(2):123–9. doi:10.1007/s10637-006-9016-5.CrossRef

34.

Yoon MS, Nam T-K, Lee J-S, Cho S-H, Song J-Y, Ahn S-J, et al. VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma. J Korean Med Sci. 2011;26(4):513–20.CrossRefPubMedPubMedCentral

35.

Kong J, Crissey MA, Stairs DB, Sepulveda AR, Lynch JP. Cox2 and beta-catenin/T-cell factor signaling intestinalize human esophageal keratinocytes when cultured under organotypic conditions. Neoplasia (New York, NY). 2011;13(9):792–805.CrossRef

36.

Möbius C, Stein HJ, Spieß C, Becker I, Feith M, Theisen J, et al. COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol. 2005;31(7):755–9. doi:10.1016/j.ejso.2005.01.006.CrossRefPubMed

37.

Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology. 2003;124(1):47–56. doi:10.1053/gast.2003.50008.CrossRefPubMed

38.

Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009;100(3):551–7.CrossRefPubMedPubMedCentral

39.

Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, et al. Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis. Gastroenterology. 2012;142(3):442–52.e5. doi:10.1053/j.gastro.2011.11.019.CrossRefPubMed

40.

Zhang S, Zhang XQ, Ding XW, Yang RK, Huang SL, Kastelein F, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett/’s esophagus: a meta-analysis. Br J Cancer. 2014;110(9):2378–88. doi:10.1038/bjc.2014.127.CrossRefPubMedPubMedCentral

41.

Davis TW, O’Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, et al. Synergy between Celecoxib and Radiotherapy Results from Inhibition of Cyclooxygenase-2-Derived Prostaglandin E2, a Survival Factor for Tumor and Associated Vasculature. Cancer Res. 2004;64(1):279–85. doi:10.1158/0008-5472.can-03-1168.CrossRefPubMed

42.

Terakado N, Shintani S, Yano J, Chunnan L, Mihara M, Nakashiro K-i, et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol. 2004;40(4):383–9. doi:10.1016/j.oraloncology.2003.09.005.CrossRefPubMed

43.

Oezcelik A, Kaiser GM, Niebel W, Sleyman C, Treckmann JW, Sotiropoulos GC, et al. Ten-year survival of esophageal cancer after an en-bloc esophagectomy. J Surg Oncol. 2012;105(3):284–7. doi:10.1002/jso.22096.CrossRefPubMed

44.

Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1120–8. doi:10.1016/j.ijrobp.2006.02.013.CrossRefPubMed

45.

Weinberg JS, Suki D, Hanbali F, Cohen ZR, Lenzi R, Sawaya R. Metastasis of esophageal carcinoma to the brain. Cancer. 2003;98(9):1925–33. doi:10.1002/cncr.11737.CrossRefPubMed

46.

Rice TW, Khuntia D, Rybicki LA, Adelstein DJ, Vogelbaum MA, Mason DP, et al. Brain Metastases From Esophageal Cancer: A Phenomenon of Adjuvant Therapy? Ann Thorac Surg. 2006;82(6):2042–9.e2. doi:10.1016/j.athoracsur.2006.06.089.CrossRefPubMed

47.

Smith RS, Miller RC. Incidence of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol. 2011;17(19):2407–10. doi:10.3748/wjg.v17.i19.2407.CrossRefPubMedPubMedCentral

Title: Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer
Authors: James M. Cleary
Harvey J. Mamon
Jackie Szymonifka
Raphael Bueno
Noah Choi
Dean M. Donahue
Panos M. Fidias
Henning A. Gaissert
Michael T. Jaklitsch
Matthew H. Kulke
Thomas P. Lynch
Steven J. Mentzer
Jeffrey A. Meyerhardt
Richard S. Swanson
John Wain
Charles S. Fuchs
Peter C. Enzinger
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-016-2485-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2016

LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study

Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma

Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ß-catenin

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy

Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study

Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer